FRFR
US • —
$61.41
P/E
23.77
PEG
0.85
FCF Yield
—
Rev Growth YoY
+8.8% YoY
Gross Margin
73.6%
Health Score
6/10
D/E Ratio
0.96
Confidence
LOW
Business Snapshot
This company operates in the US market, and an 11.5x price-to-sales ratio suggests it engages in a high-margin business model, evidenced by its 73.6% gross margin. It maintains a strong net margin of 46.0%, indicating efficient cost control and pricing power. With a market capitalisation that is not available in the provided data, its financial scale cannot be precisely determined. The company holds a niche competitive position within its sector, supported by a P/E ratio of 23.77x that is near the sector average, suggesting it is not an extreme outlier in valuation. A defining characteristic is its consistent earnings performance, having beaten analyst estimates in all 4 of the most recent quarters.
Financial Health
The company demonstrates strong profitability with a gross margin of 73.6% and a net margin of 46.0%, reflecting a high-margin business model. The balance sheet appears reasonably healthy, with a debt-to-equity ratio of 0.96x and a current ratio of 1.74x, indicating a manageable debt load and sufficient short-term liquidity to cover liabilities...
Risk Assessment
- VALUATION — The price-to-sales ratio of 11.5x is high, which can leave the stock vulnerable to sharp corrections if growth expectations are not met.
- EARNINGS QUALITY — While the company has beaten estimates 4 out of 4 quarters, this perfect track record could indicate that estimates are set to be beaten, rather than reflecting underlying business strength.
- DEBT / LIQUIDITY — Although manageable, the debt-to-equity ratio of 0.96x is close to 1.0, meaning the company uses a moderate amount of debt that could become a burden in a rising-rate environment.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....
The company demonstrates strong profitability with a gross margin of 73.6% and a net margin of 46.0%, reflecting a high-margin business model. The balance sheet appears reasonably healthy, with a debt-to-equity ratio of 0.96x and a current ratio of 1.74x, indicating a manageable debt load and sufficient short-term liquidity to cover liabilities. Free cash flow data is not available, making it impossible to assess the company's actual cash generation or its FCF yield. The return on equity stands at a solid 12.8%, showing effective use of shareholder capital. While the margins are impressive and the balance sheet is not stretched, the lack of free cash flow data introduces uncertainty about the company's ability to self-fund growth or consistently return capital to shareholders.
- VALUATION — The price-to-sales ratio of 11.5x is high, which can leave the stock vulnerable to sharp corrections if growth expectations are not met. - EARNINGS QUALITY — While the company has beaten estimates 4 out of 4 quarters, this perfect track record could indicate that estimates are set to be beaten, rather than reflecting underlying business strength. - DEBT / LIQUIDITY — Although manageable, the debt-to-equity ratio of 0.96x is close to 1.0, meaning the company uses a moderate amount of debt that could become a burden in a rising-rate environment. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives